CTRI/2026/02/0104945Not yet recruitingPhase 3
A Phase 3, Open label Extension Study to Evaluate the Long term Safety and Tolerability of KarXT and KarX EC for the Treatment of Agitation Associated with Alzheimer Disease (ADAGIO 3)
Bristol Myers Squibb India Private Limited7 sites in 1 country600 target enrollmentStarted: July 21, 2026Last updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 600
- Locations
- 7
- Primary Endpoint
- Incidence of any TEAEs
Study Overview
Brief Summary
The primary objective of this OLEstudy isto evaluate thelong-termsafety and tolerability of
KarXT+ KarX-EC in the treatment of participants with agitation associated with AD.
Study Duration: maximum duration after screening for each participant will be 30 weeks.
Study Intervention Duration - The study includes up to a 26-weekopen-label treatment period and
a SFU visit 4 weeks following the EOT.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Masking
- None
Eligibility Criteria
- Ages
- 55.00 Year(s) to 90.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Participants are eligible to be included in the study only if all of the following criteria apply.
- •Participants must have completed study CN0120023 or CN0120024per protocol. Signed Written Informed Consent 2)Participants (or their LAR, see APPENDIX 1) must have signed and dated an IRB or IEC-approved written ICF in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol-related procedures that are not part of normal patient care. If the participant is deemed not competent to provide IC, the participant should provide informed assent, if required by local regulations. 3)Have one identified caregiver who should have sufficient contact (approximately 10 hours a week or more) and is willing to:.
- •Attend all visits and report on participants status.
- •Oversee participant compliance with medication and study procedures.
- •Participate in the study assessments and provide IC to participate in the study.
- •The caregiver role in non-institutionalized settings may or may not be the same individual who fulfills the role of caretaker. In institutionalized settings (eg, nursing homes or memory care facilities), a caregiver may be a staff member of the institutionalized setting or another individual (eg, family member, family friend, hired professional caregiver) who fulfills the above criteria.
Exclusion Criteria
- •Participants are excludedfrom the study if any of the following criteria apply- Medical Conditions 1)History or presence (including those that could have developed during study CN0120023 or CN0120024) of clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, GI,eg, obstructive disorders (including conditions that may decrease GI motility, such as ulcerative colitis, intestinal atony, and myasthenia gravis), endocrine, immunologic, dermatologic, neurologic,or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
- •All grades of hepatic impairment (mild [Child-Pugh Class A), moderate(Child-Pugh Class B), and severe (Child-Pugh Class C)).
- •If, in the opinion of the Investigator and or Sponsor OR Medical Monitor, participant is unsuitable for enrollment in the study or participant has any finding that, in the view of the Investigator and OR or Sponsor OR Medical Monitor, may compromise the safety of the participant or affect his or her ability to adhere to the protocol visit schedule or fulfill visit requirements.
- •Risk of suicidal behavior during the study as determined by the Investigators clinical assessment and OR or C-SSRS as confirmed by the following: i)Answers Yes on items 3, 4, or 5 (C-SSRS –ideation) with the most recent episode occurring within the 2 months before screening or, ii)Answers Yes to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before Screening Physical and Laboratory Test Findings 5)An eGFR of less than or equal to 50mL per min at screening.
- •Elevations in hepatic transaminases at screening greater than or equal to 2× ULN for ALT and AST 7)Bilirubin greater than 2× ULN, unless in the context of Gilberts syndrome.
- •History of unstable hypertension or tachycardia as evidenced by- i)Blood pressure of greater than or equal to 160 or 100 mmHg (average of triplicate seated measures) at screening ii)Heart rate of greater than or equal to 100 bpm (average of triplicate seated measures) at screening 9)Urine toxicology screen positive for phencyclidine, amphetamines, opiates, cocaine, or alcohol (clinically significant alcohol use in the opinion of the Investigator) 10)Clinically significant abnormal finding on the physical examination, medical history, ECG (QTcF of greater than 450 msec in males and greater than 470 msec in females), or clinical laboratory results at Screening.
Outcomes
Primary Outcomes
Incidence of any TEAEs
Time Frame: 26 weeks
Secondary Outcomes
- Body weight and BMI(26 weeks)
- Reported AEs, TEAEs, SAEs, TEAEs leading to study(withdrawal and deaths)
- AESI(26 weeks)
- BARS and AIMS(26 weeks)
- Orthostatic vital signs (supine and standing OR sitting(and standing after 2 minutes): blood pressure (systolic)
- Clinical laboratory evaluations(26 weeks)
- 12-lead ECG(26 weeks)
- Suicidal ideation assessed using the C-SSRS(26 weeks)
- Assessment of cognition as measured by MMSE and(ADAS-Cog-13)
- Assessment of severity of benign prostatic hyperplasia(as measured by IPSS in male participant)
- Mean change from baseline to the end of Week 26 of EOT(on -)
- Change from baseline for biomarkers of(neurodegeneration and neuroinflammation over the)
Investigators
Shilpi Sinha
Bristol Myers Squibb
Study Sites (7)
Loading locations...
Similar Trials
Recruiting
Phase 3
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, RespectivelySchizophreniaNCT07424404Karuna Therapeutics, Inc., a Bristol Myers Squibb company400
Recruiting
Phase 3
A Phase 3, Parallel Group Study to Evaluate KarXT as a Treatment for Psychosis Associated with Alzheimer’s Disease2024-516363-92-00Bristol-Myers Squibb Services Unlimited Company93
Recruiting
Phase 3
A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of SchizophreniaSchizophrenia2024-510773-20-00Karuna Therapeutics Inc.50
Recruiting
Phase 3
An Open-Label Extension Study of Fazirsiran2023-503497-21-00Takeda Development Center Americas Inc.18
Recruiting
Phase 2
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseNCT07399704Azafaros B.V.21